ENZO BIOCHEM INC (ENZ) Fundamental Analysis & Valuation

NYSE:ENZ • US2941001024

Current stock price

0.3138 USD
-0.07 (-17.77%)
At close:
0.32 USD
+0.01 (+1.98%)
After Hours:

This ENZ fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ENZ Profitability Analysis

1.1 Basic Checks

  • In the past year ENZ has reported negative net income.
  • In the past year ENZ has reported a negative cash flow from operations.
  • In multiple years ENZ reported negative net income over the last 5 years.
  • In the past 5 years ENZ reported 4 times negative operating cash flow.
ENZ Yearly Net Income VS EBIT VS OCF VS FCFENZ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

1.2 Ratios

  • The Return On Assets of ENZ (-31.57%) is worse than 86.67% of its industry peers.
  • ENZ has a Return On Equity of -45.72%. This is in the lower half of the industry: ENZ underperforms 71.43% of its industry peers.
Industry RankSector Rank
ROA -31.57%
ROE -45.72%
ROIC N/A
ROA(3y)-12.64%
ROA(5y)-11.26%
ROE(3y)-18.05%
ROE(5y)-18.29%
ROIC(3y)N/A
ROIC(5y)N/A
ENZ Yearly ROA, ROE, ROICENZ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

1.3 Margins

  • ENZ has a better Gross Margin (44.74%) than 74.29% of its industry peers.
  • In the last couple of years the Gross Margin of ENZ has grown nicely.
  • The Profit Margin and Operating Margin are not available for ENZ so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.26%
GM growth 5Y9.93%
ENZ Yearly Profit, Operating, Gross MarginsENZ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ENZ Health Analysis

2.1 Basic Checks

  • ENZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ENZ has been increased compared to 1 year ago.
  • Compared to 5 years ago, ENZ has more shares outstanding
  • Compared to 1 year ago, ENZ has an improved debt to assets ratio.
ENZ Yearly Shares OutstandingENZ Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ENZ Yearly Total Debt VS Total AssetsENZ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -5.09, we must say that ENZ is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -5.09, ENZ is doing worse than 87.62% of the companies in the same industry.
  • A Debt/Equity ratio of 0.00 indicates that ENZ is not too dependend on debt financing.
  • ENZ's Debt to Equity ratio of 0.00 is amongst the best of the industry. ENZ outperforms 84.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.09
ROIC/WACCN/A
WACC9.89%
ENZ Yearly LT Debt VS Equity VS FCFENZ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • ENZ has a Current Ratio of 3.04. This indicates that ENZ is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 3.04, ENZ belongs to the best of the industry, outperforming 86.67% of the companies in the same industry.
  • ENZ has a Quick Ratio of 2.69. This indicates that ENZ is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of ENZ (2.69) is better than 81.90% of its industry peers.
Industry RankSector Rank
Current Ratio 3.04
Quick Ratio 2.69
ENZ Yearly Current Assets VS Current LiabilitesENZ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. ENZ Growth Analysis

3.1 Past

  • The earnings per share for ENZ have decreased strongly by -430.17% in the last year.
  • The Revenue for ENZ has decreased by -54.20% in the past year. This is quite bad
  • The Revenue for ENZ have been decreasing by -17.04% on average. This is quite bad
EPS 1Y (TTM)-430.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.17%
Revenue 1Y (TTM)-54.2%
Revenue growth 3Y-35.29%
Revenue growth 5Y-17.04%
Sales Q2Q%-14.3%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENZ Yearly Revenue VS EstimatesENZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ENZ Yearly EPS VS EstimatesENZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2022 -0.1 -0.2 -0.3

More info and screens

Find the best growth stocksShow best growing peers

0

4. ENZ Valuation Analysis

4.1 Price/Earnings Ratio

  • ENZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENZ Price Earnings VS Forward Price EarningsENZ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENZ Per share dataENZ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 0.6 0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. ENZ Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 31.87%, ENZ is a good candidate for dividend investing.
  • In the last 3 months the price of ENZ has falen by -52.09%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
  • ENZ's Dividend Yield is rather good when compared to the industry average which is at 0.50. ENZ pays more dividend than 100.00% of the companies in the same industry.
  • ENZ's Dividend Yield is rather good when compared to the S&P500 average which is at 1.91.
Industry RankSector Rank
Dividend Yield 31.87%

5.2 History

  • ENZ is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
ENZ Yearly Dividends per shareENZ Yearly Dividends per shareYearly Dividends per share 2024 0.02 0.04 0.06 0.08

5.3 Sustainability

DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
ENZ Yearly Income VS Free CF VS DividendENZ Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

More info and screens

Find the best dividend stocksShow peers with best dividend

ENZ Fundamentals: All Metrics, Ratios and Statistics

ENZO BIOCHEM INC

NYSE:ENZ (4/17/2025, 8:15:28 PM)

After market: 0.32 +0.01 (+1.98%)

0.3138

-0.07 (-17.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-17
Earnings (Next)06-11
Inst Owners34.1%
Inst Owner Change-45.05%
Ins Owners10.57%
Ins Owner Change0%
Market Cap16.44M
Revenue(TTM)29.09M
Net Income(TTM)-21.31M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 31.87%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.57
P/FCF N/A
P/OCF N/A
P/B 0.35
P/tB 0.35
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.56
BVpS0.89
TBVpS0.89
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.57%
ROE -45.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.74%
FCFM N/A
ROA(3y)-12.64%
ROA(5y)-11.26%
ROE(3y)-18.05%
ROE(5y)-18.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.26%
GM growth 5Y9.93%
F-Score3
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 57.14%
Cap/Sales 2.69%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.04
Quick Ratio 2.69
Altman-Z -5.09
F-Score3
WACC9.89%
ROIC/WACCN/A
Cap/Depr(3y)89.52%
Cap/Depr(5y)102.77%
Cap/Sales(3y)7.08%
Cap/Sales(5y)5.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-430.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.17%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-54.2%
Revenue growth 3Y-35.29%
Revenue growth 5Y-17.04%
Sales Q2Q%-14.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y77.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.68%
OCF growth 3YN/A
OCF growth 5YN/A

ENZO BIOCHEM INC / ENZ Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ENZO BIOCHEM INC (ENZ) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ENZ.


What is the valuation status for ENZ stock?

ChartMill assigns a valuation rating of 0 / 10 to ENZO BIOCHEM INC (ENZ). This can be considered as Overvalued.


What is the profitability of ENZ stock?

ENZO BIOCHEM INC (ENZ) has a profitability rating of 1 / 10.


What is the financial health of ENZO BIOCHEM INC (ENZ) stock?

The financial health rating of ENZO BIOCHEM INC (ENZ) is 5 / 10.